ClinicalTrials.gov
A service of the U.S. National Institutes of Health

Example: "Heart attack" AND "Los Angeles"
Search for studies:
Search

Advanced Search | Help | Studies by Topic | Glossary

Find Studies | About Clinical Studies | Submit Studies | Resources | About This Site

Home > Find Studies > Search Results > Study Record Detail
Text Size

Trial record **1 of 1** for: NCT00788710
Previous Study | Return to List | Next Study

A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)

This study has been completed.

Sponsor:
Merck Sharp & Dohme Corp.

Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

ClinicalTrials.gov Identifier:
NCT00788710

First received: November 5, 2008
Last updated: November 30, 2015
Last verified: November 2015
History of Changes

Full Text View | Tabular View | Study Results | Disclaimer | How to Read a Study Record

Purpose

The purpose of this study is to evaluate the efficacy and safety of etoricoxib compared to placebo in the treatment of postoperative pain associated with total abdominal hysterectomy.

Condition	Intervention	Phase
Acute Pain Following a Total Abdominal Hysterectomy	Drug: etoricoxib (MK0663) 120 mg Drug: Comparator: Placebo Drug: etoricoxib (MK0663) 90 mg	Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Official Title: A Double-Blind, Placebo-Controlled, Multicenter Trial to Study the Efficacy and Tolerability of MK0663/Etoricoxib in the Treatment of Pain After Abdominal Hysterectomy

Resource links provided by NLM:

MedlinePlus related topics: Hysterectomy

U.S. FDA Resources

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:

- Average Pain Intensity at Rest Over Days 1 to 3 [Time Frame: 3 Days] [Designated as safety issue: No]

Pain intensity at rest was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.

Secondary Outcome Measures:

- Average Total Daily Dose of Morphine Over Days 1 to 3 [Time Frame: 3 days] [Designated as safety issue: No]
- Average Elicited Pain Upon Sitting Over Days 1 to 3 [Time Frame: 3 days] [Designated as safety issue: No]

  Elicited pain upon sitting was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.

Enrollment:	430
Study Start Date:	October 2008
Study Completion Date:	July 2010
Primary Completion Date:	July 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Etoricoxib 120 mg etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.	Drug: etoricoxib (MK0663) 120 mg 120 mg of etoricoxib (MK0663) for a total of 5 days Other Name: Arcoxia
Experimental: Etoricoxib 90 mg etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.	Drug: etoricoxib (MK0663) 90 mg 90 mg of etoricoxib (MK0663) for a total of 5 days
Placebo Comparator: Placebo Placebo- 3 tablets once daily	Drug: Comparator: Placebo Placebo tablets once daily on Days 1-5. Total treatment is 5 days.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

- Patients 18 years or older in generally good health who are scheduled to have a total hysterectomy and who are willing to limit alcohol consumption

Exclusion Criteria:

- Patient is allergic to the study drug, other cyclooxygenase-2 (COX-2) inhibitors/nonsteroidal anti-inflammatory drugs (NSAIDS), ibuprofen, morphine, or oxycodone or has hypersensitivity to aspirin or other NSAIDS
- Patient has uncontrolled high blood pressure
- Patient has a history of drug and/or alcohol abuse within the last 5 years
- Patient has taken part in another investigational study within 4 weeks of the start of study
- Patient is breast-feeding
- Patient has an active ulcer or inflammatory bowel disease

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00788710

Sponsors and Collaborators

Merck Sharp & Dohme Corp.

Investigators

Study Director: Medical Monitor Merck Sharp & Dohme Corp.

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Viscusi ER, Frenkl TL, Hartrick CT, Rawal N, Kehlet H, Papanicolaou D, Gammaitoni A, Ko AT, Morgan LM, Mehta A, Curtis SP, Peloso PM. Perioperative use of etoricoxib reduces pain and opioid side-effects after total abdominal hysterectomy: a double-blind, randomized, placebo-controlled phase III study. Curr Med Res Opin. 2012 Aug;28(8):1323-35. doi: 10.1185/03007995.2012.707121. Epub 2012 Jul 16.

Responsible Party:	Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:	NCT00788710 History of Changes
Other Study ID Numbers:	0663-097 2008_578
Study First Received:	November 5, 2008
Results First Received:	June 22, 2011
Last Updated:	November 30, 2015
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Acute Pain	Central Nervous System Agents
Nervous System Diseases	Cyclooxygenase 2 Inhibitors
Neurologic Manifestations	Cyclooxygenase Inhibitors
Pain	Enzyme Inhibitors
Signs and Symptoms	Molecular Mechanisms of Pharmacological Action
Etoricoxib	Peripheral Nervous System Agents
Analgesics	Pharmacologic Actions
Analgesics, Non-Narcotic	Physiological Effects of Drugs
Anti-Inflammatory Agents	Sensory System Agents
Anti-Inflammatory Agents, Non-Steroidal	Therapeutic Uses
Antirheumatic Agents	

ClinicalTrials.gov processed this record on April 14, 2016

TO TOP

For Patients and Families | For Researchers | For Study Record Managers

HOME RSS FEEDS SITE MAP TERMS AND CONDITIONS DISCLAIMER CONTACT NLM HELP DESK

Copyright | Privacy | Accessibility | Viewers and Players | Freedom of Information Act | USA.gov
U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health and Human Services

ClinicalTrials.gov
A service of the U.S. National Institutes of Health

Example: "Heart attack" AND "Los Angeles"
Search for studies:
Search

Advanced Search | Help | Studies by Topic | Glossary

Find Studies | About Clinical Studies | Submit Studies | Resources | About This Site

Home > Find Studies > Search Results > Study Record Detail
Text Size

Trial record **1 of 1** for: NCT00788710
Previous Study | Return to List | Next Study

A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)

This study has been completed.

Sponsor:
Merck Sharp & Dohme Corp.

Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

ClinicalTrials.gov Identifier:
NCT00788710

First received: November 5, 2008
Last updated: November 30, 2015
Last verified: November 2015
History of Changes

Full Text View | Tabular View | Study Results | Disclaimer | How to Read a Study Record

Results First Received: June 22, 2011

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Investigator); Primary Purpose: Treatment
Condition:	Acute Pain Following a Total Abdominal Hysterectomy
Interventions:	Drug: etoricoxib (MK0663) 120 mg Drug: Comparator: Placebo Drug: etoricoxib (MK0663) 90 mg

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Etoricoxib 120 mg	Etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
Etoricoxib 90 mg	Etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
Placebo	Placebo - 3 tablets once daily on Days 1-5. Total treatment is 5 days.

Participant Flow: Overall Study

	Etoricoxib 120 mg	Etoricoxib 90 mg	Placebo
STARTED	144	142	144
COMPLETED	139	134	138
NOT COMPLETED	5	8	6
Adverse Event	1	3	4
Lack of Efficacy	0	0	1
Lost to Follow-up	0	1	0
Physician Decision	2	1	0
Protocol Violation	0	1	1
Withdrawal by Subject	2	2	0

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Etoricoxib 120 mg	Etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
Etoricoxib 90 mg	Etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
Placebo	Placebo - 3 tablets once daily on Days 1-5. Total treatment is 5 days.
Total	Total of all reporting groups

Baseline Measures

	Etoricoxib 120 mg	Etoricoxib 90 mg	Placebo	Total
Number of Participants				

[units: participants]	**144**	**142**	**144**	**430**
Age [units: years] Mean (Standard Deviation)	**46.3 (6.9)**	**47.0 (7.2)**	**45.7 (7.0)**	**46.3 (7.0)**
Gender [units: participants]				
Female	**144**	**142**	**144**	**430**
Male	**0**	**0**	**0**	**0**

Outcome Measures

Hide All Outcome Measures

1. Primary: Average Pain Intensity at Rest Over Days 1 to 3 [Time Frame: 3 Days]

Measure Type	Primary
Measure Title	Average Pain Intensity at Rest Over Days 1 to 3
Measure Description	Pain intensity at rest was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.
Time Frame	3 Days
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Full analysis set population

Reporting Groups

	Description
Etoricoxib 120 mg	Etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
Etoricoxib 90 mg	Etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
Placebo	Placebo - 3 tablets once daily on Days 1-5. Total treatment is 5 days.

Measured Values

	Etoricoxib 120 mg	**Etoricoxib 90 mg**	**Placebo**
Number of Participants Analyzed [units: participants]	**133**	**127**	**135**
Average Pain Intensity at Rest Over Days 1 to 3 [units: Score on a scale] Least Squares Mean (Standard Error)	**2.40 (0.15)**	**2.46 (0.15)**	**3.26 (0.15)**

Statistical Analysis 1 for Average Pain Intensity at Rest Over Days 1 to 3

Groups [1]	Etoricoxib 120 mg vs. Placebo
Method [2]	ANOVA
P Value [3]	<0.001

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	No text entered.
[2]	Other relevant method information, such as adjustments or degrees of freedom:
	No text entered.
[3]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
	No text entered.

Statistical Analysis 2 for Average Pain Intensity at Rest Over Days 1 to 3

Groups [1]	Etoricoxib 90 mg vs. Placebo
Method [2]	ANOVA
P Value [3]	<0.001

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	No text entered.
[2]	Other relevant method information, such as adjustments or degrees of freedom:
	No text entered.
[3]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
	No text entered.

2. Secondary: Average Total Daily Dose of Morphine Over Days 1 to 3 [Time Frame: 3 days]

Measure Type	Secondary
Measure Title	Average Total Daily Dose of Morphine Over Days 1 to 3
Measure Description	No text entered.
Time Frame	3 days
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Full analysis set population

Reporting Groups

	Description

Etoricoxib 120 mg	Etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
Etoricoxib 90 mg	Etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
Placebo	Placebo - 3 tablets once daily on Days 1-5. Total treatment is 5 days.

Measured Values

	Etoricoxib 120 mg	Etoricoxib 90 mg	Placebo
Number of Participants Analyzed [units: participants]	**132**	**130**	**134**
Average Total Daily Dose of Morphine Over Days 1 to 3 [units: milligrams (mg)] Least Squares Mean (Standard Error)	**5.37 (0.08)**	**5.46 (0.08)**	**7.75 (0.08)**

Statistical Analysis 1 for Average Total Daily Dose of Morphine Over Days 1 to 3

Groups [1]	Etoricoxib 120 mg vs. Placebo
Method [2]	ANOVA
P Value [3]	<0.001

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	No text entered.
[2]	Other relevant method information, such as adjustments or degrees of freedom:
	No text entered.
[3]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
	No text entered.

Statistical Analysis 2 for Average Total Daily Dose of Morphine Over Days 1 to 3

Groups [1]	Etoricoxib 90 mg vs. Placebo
Method [2]	ANOVA
P Value [3]	<0.001

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	No text entered.
[2]	Other relevant method information, such as adjustments or degrees of freedom:
	No text entered.
[3]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
	No text entered.

3. Secondary: Average Elicited Pain Upon Sitting Over Days 1 to 3 [Time Frame: 3 days]

Measure Type	Secondary
Measure Title	Average Elicited Pain Upon Sitting Over Days 1 to 3
Measure Description	Elicited pain upon sitting was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.
Time Frame	3 days
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Full analysis set population

Reporting Groups

	Description
Etoricoxib 120 mg	Etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
Etoricoxib 90 mg	Etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
Placebo	Placebo - 3 tablets once daily on Days 1-5. Total treatment is 5 days.

Measured Values

	Etoricoxib 120 mg	**Etoricoxib 90 mg**	**Placebo**
Number of Participants Analyzed [units: participants]	**133**	**127**	**135**
Average Elicited Pain Upon Sitting Over Days 1 to 3 [units: Score on a scale] Least Squares Mean (Standard Error)	**3.58 (0.17)**	**3.80 (0.17)**	**4.71 (0.17)**

Statistical Analysis 1 for Average Elicited Pain Upon Sitting Over Days 1 to 3

Groups [1]	Etoricoxib 120 mg vs. Placebo
Method [2]	ANOVA
P Value [3]	<0.001

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	No text entered.
[2]	Other relevant method information, such as adjustments or degrees of freedom:
	No text entered.
[3]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
	No text entered.

Statistical Analysis 2 for Average Elicited Pain Upon Sitting Over Days 1 to 3

Groups [1]	Etoricoxib 90 mg vs. Placebo
Method [2]	ANOVA
P Value [3]	<0.001

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	No text entered.
[2]	Other relevant method information, such as adjustments or degrees of freedom:
	No text entered.
[3]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
	No text entered.

Serious Adverse Events

Hide Serious Adverse Events

Time Frame	No text entered.
Additional Description	No text entered.

Reporting Groups

	Description
Etoricoxib 120 mg	Etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
Etoricoxib 90 mg	Etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
Placebo	Placebo - 3 tablets once daily on Days 1-5. Total treatment is 5 days.

Serious Adverse Events

	Etoricoxib 120 mg	Etoricoxib 90 mg	Placebo
Total, serious adverse events			
# participants affected / at risk	**5/144 (3.47%)**	**5/142 (3.52%)**	**10/144 (6.94%)**
Gastrointestinal disorders			
Abdominal pain [1]			
# participants affected / at risk	**1/144 (0.69%)**	**0/142 (0.00%)**	**0/144 (0.00%)**
# events	**1**	**0**	**0**
Faecaloma [1]			
# participants affected / at risk	**0/144 (0.00%)**	**1/142 (0.70%)**	**0/144 (0.00%)**
# events	**0**	**1**	**0**

Small intestinal obstruction [1]			
# participants affected / at risk	**1/144 (0.69%)**	**0/142 (0.00%)**	**0/144 (0.00%)**
# events	**1**	**0**	**0**
Infections and infestations			
Cellulitis [1]			
# participants affected / at risk	**0/144 (0.00%)**	**0/142 (0.00%)**	**1/144 (0.69%)**
# events	**0**	**0**	**1**
Postoperative wound infection [1]			
# participants affected / at risk	**0/144 (0.00%)**	**0/142 (0.00%)**	**1/144 (0.69%)**
# events	**0**	**0**	**1**
Vaginal abscess [1]			
# participants affected / at risk	**0/144 (0.00%)**	**0/142 (0.00%)**	**1/144 (0.69%)**
# events	**0**	**0**	**1**
Injury, poisoning and procedural complications			
Operative haemorrhage [1]			
# participants affected / at risk	**0/144 (0.00%)**	**1/142 (0.70%)**	**0/144 (0.00%)**
# events	**0**	**1**	**0**
Post procedural haematoma [1]			
# participants affected / at risk	**0/144 (0.00%)**	**0/142 (0.00%)**	**1/144 (0.69%)**
# events	**0**	**0**	**1**
Post procedural haemorrhage [1]			
# participants affected / at risk	**0/144 (0.00%)**	**0/142 (0.00%)**	**1/144 (0.69%)**
# events	**0**	**0**	**1**
Metabolism and nutrition disorders			
Hypokalaemia [1]			
# participants affected / at risk	**0/144 (0.00%)**	**1/142 (0.70%)**	**0/144 (0.00%)**
# events	**0**	**1**	**0**
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Endometrial cancer [1]			
# participants affected / at risk	**1/144 (0.69%)**	**0/142 (0.00%)**	**0/144 (0.00%)**
# events	**1**	**0**	**0**
Fallopian tube cancer [1]			
# participants affected / at risk	**1/144 (0.69%)**	**0/142 (0.00%)**	**0/144 (0.00%)**
# events	**1**	**0**	**0**
Uterine cancer [1]			
# participants affected / at risk	**0/144 (0.00%)**	**1/142 (0.70%)**	**0/144 (0.00%)**
# events	**0**	**1**	**0**
Nervous system disorders			
Syncope [1]			
# participants affected / at risk	**0/144 (0.00%)**	**0/142 (0.00%)**	**1/144 (0.69%)**
# events	**0**	**0**	**1**
Reproductive system and breast disorders			
Vaginal haematoma [1]			

# participants affected / at risk	0/144 (0.00%)	0/142 (0.00%)	1/144 (0.69%)
# events	0	0	1
Vaginal haemorrhage [1]			
# participants affected / at risk	0/144 (0.00%)	1/142 (0.70%)	0/144 (0.00%)
# events	0	1	0
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism [1]			
# participants affected / at risk	1/144 (0.69%)	0/142 (0.00%)	1/144 (0.69%)
# events	1	0	1
Respiratory depression [1]			
# participants affected / at risk	0/144 (0.00%)	1/142 (0.70%)	0/144 (0.00%)
# events	0	1	0
Vascular disorders			
Hypertension [1]			
# participants affected / at risk	0/144 (0.00%)	0/142 (0.00%)	1/144 (0.69%)
# events	0	0	1
Phlebitis [1]			
# participants affected / at risk	0/144 (0.00%)	0/142 (0.00%)	1/144 (0.69%)
# events	0	0	1

1 Term from vocabulary, MedDRA 13.0

Other Adverse Events

Hide Other Adverse Events

Time Frame	No text entered.
Additional Description	No text entered.

Frequency Threshold

Threshold above which other adverse events are reported	5%

Reporting Groups

	Description
Etoricoxib 120 mg	Etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
Etoricoxib 90 mg	Etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
Placebo	Placebo - 3 tablets once daily on Days 1-5. Total treatment is 5 days.

Other Adverse Events

	Etoricoxib 120 mg	Etoricoxib 90 mg	Placebo
Total, other (not including serious) adverse events			

# participants affected / at risk	60/144 (41.67%)	51/142 (35.92%)	65/144 (45.14%)
Gastrointestinal disorders			
Constipation [1]			
# participants affected / at risk	16/144 (11.11%)	12/142 (8.45%)	18/144 (12.50%)
# events	17	13	20
Flatulence [1]			
# participants affected / at risk	7/144 (4.86%)	14/142 (9.86%)	12/144 (8.33%)
# events	7	14	12
Nausea [1]			
# participants affected / at risk	40/144 (27.78%)	31/142 (21.83%)	38/144 (26.39%)
# events	41	35	43
Vomiting [1]			
# participants affected / at risk	10/144 (6.94%)	7/142 (4.93%)	10/144 (6.94%)
# events	10	7	10
General disorders			
Pyrexia [1]			
# participants affected / at risk	7/144 (4.86%)	4/142 (2.82%)	24/144 (16.67%)
# events	7	4	27
Nervous system disorders			
Dizziness [1]			
# participants affected / at risk	12/144 (8.33%)	9/142 (6.34%)	14/144 (9.72%)
# events	12	9	14
Headache [1]			
# participants affected / at risk	9/144 (6.25%)	8/142 (5.63%)	14/144 (9.72%)
# events	11	8	14
Skin and subcutaneous tissue disorders			
Pruritus [1]			
# participants affected / at risk	5/144 (3.47%)	13/142 (9.15%)	6/144 (4.17%)
# events	5	14	6

1 Term from vocabulary, MedDRA 13.0

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data

11 participants were screened & 10 participants were randomized at site 0028. An audit showed study medication dispensing logs were not kept. These 10 participants were invalidated and excluded from both efficacy & safety analyses.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are **NOT** employed by the organization sponsoring the study.

There **IS** an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

☐ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is **less than or equal to 60 days**. The sponsor cannot require changes to the communication and cannot extend the embargo.

☐ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is **more than 60 days but less than or equal to 180 days**. The sponsor cannot require changes to the communication and cannot extend the embargo.

Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

☑ **Restriction Description:** The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.

Results Point of Contact:

Name/Title: Senior Vice President, Global Clinical Development
Organization: Merck Sharp & Dohme Corp
e-mail: ClinicalTrialsDisclosure@merck.com

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Viscusi ER, Frenkl TL, Hartrick CT, Rawal N, Kehlet H, Papanicolaou D, Gammaitoni A, Ko AT, Morgan LM, Mehta A, Curtis SP, Peloso PM. Perioperative use of etoricoxib reduces pain and opioid side-effects after total abdominal hysterectomy: a double-blind, randomized, placebo-controlled phase III study. Curr Med Res Opin. 2012 Aug;28(8):1323-35. doi: 10.1185/03007995.2012.707121. Epub 2012 Jul 16.

Responsible Party:	Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:	NCT00788710 History of Changes
Other Study ID Numbers:	0663-097 2008_578
Study First Received:	November 5, 2008
Results First Received:	June 22, 2011
Last Updated:	November 30, 2015
Health Authority:	United States: Food and Drug Administration

TO TOP

For Patients and Families | For Researchers | For Study Record Managers

HOME RSS FEEDS SITE MAP TERMS AND CONDITIONS DISCLAIMER CONTACT NLM HELP DESK

Copyright | Privacy | Accessibility | Viewers and Players | Freedom of Information Act | USA.gov
U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health and Human Services